290 related articles for article (PubMed ID: 9496384)
1. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.
Voldborg BR; Damstrup L; Spang-Thomsen M; Poulsen HS
Ann Oncol; 1997 Dec; 8(12):1197-206. PubMed ID: 9496384
[TBL] [Abstract][Full Text] [Related]
2. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.
Earp HS; Dawson TL; Li X; Yu H
Breast Cancer Res Treat; 1995 Jul; 35(1):115-32. PubMed ID: 7612898
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy.
Habban Akhter M; Sateesh Madhav N; Ahmad J
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1188-1198. PubMed ID: 29991287
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
Mitchell RA; Luwor RB; Burgess AW
Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
[TBL] [Abstract][Full Text] [Related]
8. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor: association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand.
Zhu HJ; Iaria J; Orchard S; Walker F; Burgess AW
Growth Factors; 2003 Mar; 21(1):15-30. PubMed ID: 12795333
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor dependence in human tumors: more than just expression?
Arteaga CL
Oncologist; 2002; 7 Suppl 4():31-9. PubMed ID: 12202786
[TBL] [Abstract][Full Text] [Related]
13. [Epidermal growth factor inhibitors].
Delbaldo C; Faivre S; Raymond E
Rev Med Interne; 2003 Jun; 24(6):372-83. PubMed ID: 12814826
[TBL] [Abstract][Full Text] [Related]
14. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ; Bleeker WK; Brännström A; von Euler A; Jansson M; Peipp M; Schneider-Merck T; Valerius T; van de Winkel JG; Parren PW
Proc Natl Acad Sci U S A; 2008 Apr; 105(16):6109-14. PubMed ID: 18427122
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
Pomerantz RG; Grandis JR
Semin Oncol; 2004 Dec; 31(6):734-43. PubMed ID: 15599851
[TBL] [Abstract][Full Text] [Related]
16. The duality of epidermal growth factor receptor (EGFR) signaling and neural stem cell phenotype: cell enhancer or cell transformer?
Ayuso-Sacido A; Graham C; Greenfield JP; Boockvar JA
Curr Stem Cell Res Ther; 2006 Sep; 1(3):387-94. PubMed ID: 18220882
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations.
Peipp M; Schneider-Merck T; Dechant M; Beyer T; Lammerts van Bueren JJ; Bleeker WK; Parren PW; van de Winkel JG; Valerius T
J Immunol; 2008 Mar; 180(6):4338-45. PubMed ID: 18322248
[TBL] [Abstract][Full Text] [Related]
18. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy.
Pedersen MW; Meltorn M; Damstrup L; Poulsen HS
Ann Oncol; 2001 Jun; 12(6):745-60. PubMed ID: 11484948
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor family in lung cancer and premalignancy.
Franklin WA; Veve R; Hirsch FR; Helfrich BA; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):3-14. PubMed ID: 11894009
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.
Buteau J; Foisy S; Joly E; Prentki M
Diabetes; 2003 Jan; 52(1):124-32. PubMed ID: 12502502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
